Abcellera Biologics Inc Cash Flow-to-Debt Ratio
Abcellera Biologics Inc cash flow-to-debt ratio. Abcellera Biologics Inc (ABCL) has a Cash Flow-to-Debt Ratio of -0.08x as of June 2026, meaning its operating cash flow of $-33.86 Million could theoretically repay 0% of its total liabilities ($411.56 Million) in one year. Check ABCL cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Abcellera Biologics Inc (2018–2025)
Cash flow-to-debt ratio of Abcellera Biologics Inc from 2018 to 2025. Historical debt coverage capacity for Abcellera Biologics Inc across 8 annual periods. Check Abcellera Biologics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Abcellera Biologics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Abcellera Biologics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Abcellera Biologics Inc. For the full cash flow conversion analysis, see ABCL cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | $-131.29 Million | $390.05 Million | ▲ +5.6% |
| 2024 | -0.36x | $-108.56 Million | $304.47 Million | ▼ -172.8% |
| 2023 | -0.13x | $-43.88 Million | $335.78 Million | ▼ -114.5% |
| 2022 | 0.90x | $277.36 Million | $307.63 Million | ▲ +7.9% |
| 2021 | 0.84x | $244.58 Million | $292.84 Million | ▲ +544.3% |
| 2020 | 0.13x | $22.69 Million | $175.03 Million | ▼ -36.3% |
| 2019 | 0.20x | $2.69 Million | $13.24 Million | ▼ -43.6% |
| 2018 | 0.36x | $3.56 Million | $9.88 Million | — |